Murali Monohar Pandey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Murali Monohar Pandey has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Himanshu Kathuria
Nusmetics Pte Ltd., E-Centre@Redhill, Singapore 139471, Singapore
7 shared publications Paramita Saha
Industrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Science, Pilani, Rajasthan 333031, India
6 shared publications- Abhijeet Ashokrao Upadhye
Birla Institute of Technology and Science Vidya Vihar Campus
2 shared publications - Deepak Chitkara
Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus Vidya Vihar, Pilani, Rajasthan, India-333031
2 shared publications - Deepak Kaushik
Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak 124001, Haryana, India
2 shared publications - Diksha Nagpal
Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak 124001, Haryana, India
2 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16  (46) , 60516-60526
A water-soluble pyrazinium-based chemosensor for TNP detection: applications in MCF-7 cancer cell imaging and fingerprint visualization
A water-soluble pyrazinium chemosensor enables selective TNP detection via turn-off response with a detection limit of 4.43 nM, demonstrating its potential applications in latent fingerprint visualization and bioimaging.
- 21 October 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16  (46) , 60516-60526
Open AccessA water-soluble pyrazinium-based chemosensor for TNP detection: applications in MCF-7 cancer cell imaging and fingerprint visualization
A water-soluble pyrazinium chemosensor enables selective TNP detection via turn-off response with a detection limit of 4.43 nM, demonstrating its potential applications in latent fingerprint visualization and bioimaging.
- Open Access
Engineering Next-Generation Taxane Nanomedicines for Clinical Translation
Background: Taxanes have been a cornerstone in the management of a wide range of cancers, including ovarian, breast, and lung cancer, owing to their microtubule-stabilizing mechanism. Despite their clinical success, their therapeutic utility remains constrained by poor aqueous solubility, a need for toxic solubilizing vehicles, unpredictable pharmacokinetics, and systemic toxicity. Nanomedicine has redefined chemotherapeutic delivery paradigms, with liposomal systems emerging as leading platforms due to their safety and scalability. Purpose: This review aims to critically evaluate the physicochemical and formulation barriers that have limited the successful development of taxane-loaded nanoformulations and to highlight how model-informed principles can be leveraged to improve drug retention, stability, and translational potential. Review Scope: Early liposomal systems faced challenges, including premature drug release and rapid carrier opsonization, limitations that are particularly relevant for compounds with unfavorable biopharmaceutical properties. For taxanes such as paclitaxel, strong partitioning into the lipid bilayer can result in membrane destabilization and premature leakage. Conventional passive loading approaches have shown limited success for these molecules, prompting exploration of active loading strategies. Remote loading utilizes transmembrane gradients to improve drug retention and loading efficiency by concentrating therapeutics within the liposomal core; however, the non-ionizable nature of taxanes restricts the applicability of this approach. Conclusions: These limitations highlight the need for a rational nanocarrier design focused on drug–lipid interactions, physicochemical optimization, surface engineering, controlled release, manufacturing feasibility, and regulatory considerations. Integrating these principles may facilitate the development of robust, scalable, and clinically relevant taxane liposomal formulations, supporting the effective translation of these natural-product-derived therapeutics into improved cancer treatment strategies.
Open AccessEngineering Next-Generation Taxane Nanomedicines for Clinical Translation
Background: Taxanes have been a cornerstone in the management of a wide range of cancers, including ovarian, breast, and lung cancer, owing to their microtubule-stabilizing mechanism. Despite their clinical success, their therapeutic utility remains constrained by poor aqueous solubility, a need for toxic solubilizing vehicles, unpredictable pharmacokinetics, and systemic toxicity. Nanomedicine has redefined chemotherapeutic delivery paradigms, with liposomal systems emerging as leading platforms due to their safety and scalability. Purpose: This review aims to critically evaluate the physicochemical and formulation barriers that have limited the successful development of taxane-loaded nanoformulations and to highlight how model-informed principles can be leveraged to improve drug retention, stability, and translational potential. Review Scope: Early liposomal systems faced challenges, including premature drug release and rapid carrier opsonization, limitations that are particularly relevant for compounds with unfavorable biopharmaceutical properties. For taxanes such as paclitaxel, strong partitioning into the lipid bilayer can result in membrane destabilization and premature leakage. Conventional passive loading approaches have shown limited success for these molecules, prompting exploration of active loading strategies. Remote loading utilizes transmembrane gradients to improve drug retention and loading efficiency by concentrating therapeutics within the liposomal core; however, the non-ionizable nature of taxanes restricts the applicability of this approach. Conclusions: These limitations highlight the need for a rational nanocarrier design focused on drug–lipid interactions, physicochemical optimization, surface engineering, controlled release, manufacturing feasibility, and regulatory considerations. Integrating these principles may facilitate the development of robust, scalable, and clinically relevant taxane liposomal formulations, supporting the effective translation of these natural-product-derived therapeutics into improved cancer treatment strategies.
- 26 August 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23  (9) , 4394-4415
Insight into the Development of Desirable Dosage Forms and Bioenabling Strategies to Improve the Food Effect of Anticancer Drugs for the Pediatric Population
The design and development of suitable dosage forms for pediatric patients face myriad challenges. Compared to other dosage forms, oral dosage forms are widely used and accepted in pediatric patients. However, oral dosage forms have their own challenges, which include the requirement for dose flexibility, limited bioavailability due to the poor solubility of the drug, safety concerns regarding excipients, and drug administration challenges for pediatric patients. The importance of research in drug delivery of anticancer drugs has increased due to poor drug solubility and the limited availability of pharmacokinetic data in pediatric patients. The poor solubility of anticancer drugs necessitates higher doses, leading to increased episodes of adverse effects. Furthermore, administering these drugs in the fed state results in bioavailability variations compared to the fasting state, which becomes more critical for pediatric patients. Therefore, it is essential to screen formulation strategies for these drugs to improve their bioavailability in the early stages of development. This review outlines key concerns of pediatric patients receiving long-term cancer drug therapy, including physiological and pharmacological challenges in the pediatric population, the impact of food on drug efficacy, and potential adverse effects associated with it. It also highlights various formulation strategies aimed at mitigating food-related variability through bioavailability enhancement. Furthermore, the review addresses the safety levels of excipients and development of age-appropriate dosage forms for the pediatric population.
- 26 August 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23  (9) , 4394-4415
Insight into the Development of Desirable Dosage Forms and Bioenabling Strategies to Improve the Food Effect of Anticancer Drugs for the Pediatric Population
The design and development of suitable dosage forms for pediatric patients face myriad challenges. Compared to other dosage forms, oral dosage forms are widely used and accepted in pediatric patients. However, oral dosage forms have their own challenges, which include the requirement for dose flexibility, limited bioavailability due to the poor solubility of the drug, safety concerns regarding excipients, and drug administration challenges for pediatric patients. The importance of research in drug delivery of anticancer drugs has increased due to poor drug solubility and the limited availability of pharmacokinetic data in pediatric patients. The poor solubility of anticancer drugs necessitates higher doses, leading to increased episodes of adverse effects. Furthermore, administering these drugs in the fed state results in bioavailability variations compared to the fasting state, which becomes more critical for pediatric patients. Therefore, it is essential to screen formulation strategies for these drugs to improve their bioavailability in the early stages of development. This review outlines key concerns of pediatric patients receiving long-term cancer drug therapy, including physiological and pharmacological challenges in the pediatric population, the impact of food on drug efficacy, and potential adverse effects associated with it. It also highlights various formulation strategies aimed at mitigating food-related variability through bioavailability enhancement. Furthermore, the review addresses the safety levels of excipients and development of age-appropriate dosage forms for the pediatric population.
- Open Access
- 2 June 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11  (23) , 34010-34016
Validation of a New LC-MS/MS Method for Rapid Quantification of Neferine: Application to Lipid Nanocarriers
Neferine, a natural alkaloid, is known for its multifaceted properties, including antioxidant, neuroprotective, anti-inflammatory, and autophagy-regulating effects. A simple, robust, specific, and sensitive analytical method is a key requirement for quantifying an analyte. Although a few methods have been reported for simultaneous estimation, none are available for the quantification of neferine alone in pharmaceutical or nutraceutical formulations. Whereas, the quantification of drugs alone is considered as a valuable requirement in the preformulation and formulation studies. In this research work, we report the development and validation of a new liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the accurate quantification of neferine in bulk and formulations. The chromatographic separation was achieved using a UPLC BEH C18 column (2.1 × 50 mm, 1.7 μm) under an isocratic elution method. The mobile phase consisted of acetonitrile (80%) and 10 mM ammonium acetate with 0.1% formic acid (20%). The flow rate of the mobile phase was set at 0.3 mL/min. The method exhibited good linearity (R2 = 0.9944) over a range of 25–600 ng/mL. High sensitivity of the method was demonstrated by the limit of detection (LOD) and limit of quantification (LOQ) values of 1.29 and 3.90 ng/mL, respectively. Results of the accuracy and precision study were in complete alignment with the ICH guidelines. The analytical method was found to be robust under varied analytical conditions. Furthermore, the method was successfully applied for the quantification of neferine in nanostructured lipid carriers in the diffusion studies. In conclusion, the newly developed and validated LC-MS/MS method is specific, sensitive, rapid, accurate, and precise for the quantification of neferine in bulk and formulated products.
- 2 June 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11  (23) , 34010-34016
Open AccessValidation of a New LC-MS/MS Method for Rapid Quantification of Neferine: Application to Lipid Nanocarriers
Neferine, a natural alkaloid, is known for its multifaceted properties, including antioxidant, neuroprotective, anti-inflammatory, and autophagy-regulating effects. A simple, robust, specific, and sensitive analytical method is a key requirement for quantifying an analyte. Although a few methods have been reported for simultaneous estimation, none are available for the quantification of neferine alone in pharmaceutical or nutraceutical formulations. Whereas, the quantification of drugs alone is considered as a valuable requirement in the preformulation and formulation studies. In this research work, we report the development and validation of a new liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the accurate quantification of neferine in bulk and formulations. The chromatographic separation was achieved using a UPLC BEH C18 column (2.1 × 50 mm, 1.7 μm) under an isocratic elution method. The mobile phase consisted of acetonitrile (80%) and 10 mM ammonium acetate with 0.1% formic acid (20%). The flow rate of the mobile phase was set at 0.3 mL/min. The method exhibited good linearity (R2 = 0.9944) over a range of 25–600 ng/mL. High sensitivity of the method was demonstrated by the limit of detection (LOD) and limit of quantification (LOQ) values of 1.29 and 3.90 ng/mL, respectively. Results of the accuracy and precision study were in complete alignment with the ICH guidelines. The analytical method was found to be robust under varied analytical conditions. Furthermore, the method was successfully applied for the quantification of neferine in nanostructured lipid carriers in the diffusion studies. In conclusion, the newly developed and validated LC-MS/MS method is specific, sensitive, rapid, accurate, and precise for the quantification of neferine in bulk and formulated products.
- 16 May 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115  (9) , 104333
Rapamycin loaded lipid-polymer hybrid nanoparticles in a topical hydrogel for the treatment of psoriasis
- 16 May 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115  (9) , 104333
Rapamycin loaded lipid-polymer hybrid nanoparticles in a topical hydrogel for the treatment of psoriasis
- Open Access
- 13 February 2026
- Published by Elsevier in SSRN Electronic Journal
Hot-melt extrusion-based nilotinib solid dispersions: development, solid-state characterization, and in-vitro evaluation
One of the significant challenge of formulation scientist is to deal with BCS Class-IV drugs. Nilotinib (NH) recognized for its potential therapeutic benefits as an anticancer agent. However, its clinical application hindered by poor solubility and permeability (BCS Class-IV drug). To enhance therapeutic efficacy of NH, primary drive of this investigation was to employ solid dispersion (SD) approach manufactured using HME technique to enhance solubility and dissolution rate. To achieve this objective, various non-cellulosic polymers including Kollidon®VA64, Soluplus®, Eudragit®L100-55 and cellulosic polymers such as HPMC phthalate-50 (HP-50), HPMC-AS, and HP-β-cyclodextrin (HP-β-CD) employed. Preliminary studies such as TGA engaged to identify polymer with higher Tg and in-silico method to check theoretical miscibility with drug. Solid-state characterization performed to detect amorphous form utilizing techniques such as DSC, PXRD. Ionic interaction of drug and polymer checked through FT-IR spectroscopy. Chemical analysis performed to check solubility whereas in-vitro dissolution in bio-relevant and discriminatory media. The findings indicated HP-50 and HP-β-CD are most promising polymers due to formation of amorphous SD of NH. Furthermore, solubility of these formulations was ~ 10 to 15 times and 1.5 to 3 times greater than actual solubility of NH in fed state simulated intestinal fluid (FeSSIF) and fasting state simulated gastric fluid (FaSSGF) media, respectively. NH-SD comprising HP-β-CD exhibited faster drug release in discriminatory media while NH-SD comprising HP-50 demonstrated faster drug release in both bio-relevant and discriminatory media compared to Tasigna®. Our study demonstrated SD approach is useful for improvement of NH dissolution in fed state media.
- 13 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessHot-melt extrusion-based nilotinib solid dispersions: development, solid-state characterization, and in-vitro evaluation
One of the significant challenge of formulation scientist is to deal with BCS Class-IV drugs. Nilotinib (NH) recognized for its potential therapeutic benefits as an anticancer agent. However, its clinical application hindered by poor solubility and permeability (BCS Class-IV drug). To enhance therapeutic efficacy of NH, primary drive of this investigation was to employ solid dispersion (SD) approach manufactured using HME technique to enhance solubility and dissolution rate. To achieve this objective, various non-cellulosic polymers including Kollidon®VA64, Soluplus®, Eudragit®L100-55 and cellulosic polymers such as HPMC phthalate-50 (HP-50), HPMC-AS, and HP-β-cyclodextrin (HP-β-CD) employed. Preliminary studies such as TGA engaged to identify polymer with higher Tg and in-silico method to check theoretical miscibility with drug. Solid-state characterization performed to detect amorphous form utilizing techniques such as DSC, PXRD. Ionic interaction of drug and polymer checked through FT-IR spectroscopy. Chemical analysis performed to check solubility whereas in-vitro dissolution in bio-relevant and discriminatory media. The findings indicated HP-50 and HP-β-CD are most promising polymers due to formation of amorphous SD of NH. Furthermore, solubility of these formulations was ~ 10 to 15 times and 1.5 to 3 times greater than actual solubility of NH in fed state simulated intestinal fluid (FeSSIF) and fasting state simulated gastric fluid (FaSSGF) media, respectively. NH-SD comprising HP-β-CD exhibited faster drug release in discriminatory media while NH-SD comprising HP-50 demonstrated faster drug release in both bio-relevant and discriminatory media compared to Tasigna®. Our study demonstrated SD approach is useful for improvement of NH dissolution in fed state media.
- Open Access
- 7 February 2026
- Published by Elsevier in SSRN Electronic Journal
α-Aminophosphonates in Minutes: Grinding-Induced, Iodine-Catalysed, Solvent-Free, One-pot Synthesis, Crystal Structure, and Anticancer Studies
An efficient and rapid one-pot, three-component protocol for the synthesis of αaminophosphonates was developed under solvent-free grindstone conditions. Molecular iodine effectively catalysed the reaction of aldehydes, amines, and diethyl phosphite, affording αaminophosphonates and bis(α-aminophosphonates) in moderate to excellent yields at room temperature in minutes. This methodology features mild, eco-friendly, and metal-free conditions, offering high selectivity and clean conversion. The resulting Kabachnik–Fields products were further derivatised to enhance their biological activity. All synthesised compounds were evaluated through molecular docking and ADME studies, wherein compound 4a3f1 exhibited the best docking score (−9.584). Selected derivatives were further assessed for in vitro anticancer activity against the MCF-7 cell line, where compound 5ab demonstrated a promising IC50 value of 9.236 (µg/mL).
- 7 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open Accessα-Aminophosphonates in Minutes: Grinding-Induced, Iodine-Catalysed, Solvent-Free, One-pot Synthesis, Crystal Structure, and Anticancer Studies
An efficient and rapid one-pot, three-component protocol for the synthesis of αaminophosphonates was developed under solvent-free grindstone conditions. Molecular iodine effectively catalysed the reaction of aldehydes, amines, and diethyl phosphite, affording αaminophosphonates and bis(α-aminophosphonates) in moderate to excellent yields at room temperature in minutes. This methodology features mild, eco-friendly, and metal-free conditions, offering high selectivity and clean conversion. The resulting Kabachnik–Fields products were further derivatised to enhance their biological activity. All synthesised compounds were evaluated through molecular docking and ADME studies, wherein compound 4a3f1 exhibited the best docking score (−9.584). Selected derivatives were further assessed for in vitro anticancer activity against the MCF-7 cell line, where compound 5ab demonstrated a promising IC50 value of 9.236 (µg/mL).
- Open Access
- 2 September 2025
- Published by MDPI AG in Antioxidants
- Vol. 14  (9) , 1078
Management and Prevention of Neurodegenerative Disorders: Can Antioxidant-Rich Dietary Interventions Help?
Neurodegenerative diseases are associated with the senescence of functional neurons, which hampers brain functions. These diseases are caused by the accumulation of reactive oxygen species, reactive nitrogen species, cholinesterase malfunction, neuronal inflammation, and mitochondrial dysfunction. The incidence of neurodegenerative disease has been on the rise. Current therapeutic interventions are expensive, exhibit poor efficacy, and have numerous side effects. Several studies have explored the potential of crucial dietary substances rich in antioxidants and micronutrients in alleviating the clinical manifestations of such deadly diseases. Consumption of sufficient antioxidants, fatty acids, and polyphenols in regular diets delays the onset of neurodegenerative diseases. Several medicinal plants, such as Withania somnifera, Curcuma longa, Panax ginseng, Ginkgo biloba, aloe vera, Punica granatum, and various phytoextracts, contain such micronutrients in reasonable amounts. Specific dietary interventions, supplements, and patterns such as the Mediterranean-DASH intervention for neurodegenerative delay, ketogenic, paleolithic, and Wahls elimination diets have been beneficial in neurodegenerative conditions. These diet interventions and other functional foods can be an attractive, non-invasive, and inexpensive approach in the management and prevention of neurodegenerative conditions. This review discusses potential pharmacological bases involved in neurodegeneration, covering mitochondrial damage, impaired mitophagy, neuroinflammation, ferroptosis, glymphatic clearance dysfunction, brain–body interactions, and disruption of vagus nerve stimulation. The review further highlights clinical diet interventions and assorted functional foods, including fruits, vegetables, vitamins, specific supplements, and special diets, for neurodegenerative conditions. The discussion extends insights into clinical research and trials of these functional foods under neurodegenerative conditions. Overall, dietary interventions show promise in the prevention and management of neurodegenerative conditions.
- 2 September 2025
- Published by MDPI AG in Antioxidants
- Vol. 14  (9) , 1078
Open AccessManagement and Prevention of Neurodegenerative Disorders: Can Antioxidant-Rich Dietary Interventions Help?
Neurodegenerative diseases are associated with the senescence of functional neurons, which hampers brain functions. These diseases are caused by the accumulation of reactive oxygen species, reactive nitrogen species, cholinesterase malfunction, neuronal inflammation, and mitochondrial dysfunction. The incidence of neurodegenerative disease has been on the rise. Current therapeutic interventions are expensive, exhibit poor efficacy, and have numerous side effects. Several studies have explored the potential of crucial dietary substances rich in antioxidants and micronutrients in alleviating the clinical manifestations of such deadly diseases. Consumption of sufficient antioxidants, fatty acids, and polyphenols in regular diets delays the onset of neurodegenerative diseases. Several medicinal plants, such as Withania somnifera, Curcuma longa, Panax ginseng, Ginkgo biloba, aloe vera, Punica granatum, and various phytoextracts, contain such micronutrients in reasonable amounts. Specific dietary interventions, supplements, and patterns such as the Mediterranean-DASH intervention for neurodegenerative delay, ketogenic, paleolithic, and Wahls elimination diets have been beneficial in neurodegenerative conditions. These diet interventions and other functional foods can be an attractive, non-invasive, and inexpensive approach in the management and prevention of neurodegenerative conditions. This review discusses potential pharmacological bases involved in neurodegeneration, covering mitochondrial damage, impaired mitophagy, neuroinflammation, ferroptosis, glymphatic clearance dysfunction, brain–body interactions, and disruption of vagus nerve stimulation. The review further highlights clinical diet interventions and assorted functional foods, including fruits, vegetables, vitamins, specific supplements, and special diets, for neurodegenerative conditions. The discussion extends insights into clinical research and trials of these functional foods under neurodegenerative conditions. Overall, dietary interventions show promise in the prevention and management of neurodegenerative conditions.
- 4 June 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 322  (Pt 1) , 144952
Characterization and evaluation of varieties of microcrystalline cellulose in formulations containing lactose incompatible drugs: Influence on compactibility and drug release
- 4 June 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 322  (Pt 1) , 144952
Characterization and evaluation of varieties of microcrystalline cellulose in formulations containing lactose incompatible drugs: Influence on compactibility and drug release